All seven brands in the study retained the slots they held in the previous Pharma Focus on migraine treatments seven months ago (PRWeek, 23 January) – with first-to-market brand Imigran scoring 98 per cent awareness among GPs.
Pfizer’s Relpax props up the table with just five per cent awareness.
Forty-five per cent of GPs were more likely to prescribe Imigran as a result of promotional messages (up from 41 per cent last time).
Second-placed Zomig’s percentage rose from 30 to 31, while that of third-placed Naramig plummeted from 30 to 22.
The other products’ results were again less posi-tive and consistent with the generally lower recognition level for these particular types of drugs among GPs.
The medical sales rep continues to be an important source of awareness for GPs and was the most frequently cited source in relation to five of the seven products profiled. The exceptions were Zomig and Relpax for which an ad in a medical journal was the most mentioned source.
Two-hundred GPs were surveyed online by NOP World Health via GP Net Surveys.
NOP World Health senior research executive Jude Ryall said: ‘Imigran and Zomig are clearly first-choice products for GPs when they are treating migraine suggesting that they are most comfortable with “tried and tested” products in this therapy area.’
NEXT MONTH: Proton pump inhibitor brands